Analytical Data
-
Gene name
EBAG9
- Application
-
Alternative Names
Cancer-associated surface antigen R;CAS1;Estrogen receptor-binding fragment-associated gene 9 protein
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O00559
-
Expression Region
28-213aa
-
Molecular Weight
37.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EBAG9 (Estrogen Receptor Binding Activity Protein 9) is a protein that has garnered significant attention in cancer research due to its involvement in tumor biology and its potential role in the modulation of estrogen receptor signaling. Initially identified as a gene regulated by estrogen, EBAG9 has been shown to be overexpressed in various malignancies, particularly in breast cancer, where it is linked to aggressive tumor characteristics and poor prognosis. The protein is thought to influence cell proliferation, apoptosis, and metastasis, positioning it as a critical player in cancer progression. Research has indicated that EBAG9 can interact with various signaling pathways, making it a target of interest for potential therapeutic interventions. Given its implications in cancer progression and its regulatory role in the estrogen signaling pathway, studies aiming to understand the molecular mechanisms underlying EBAG9 function and its contribution to tumorigenesis are essential. Scientists are exploring the development of EBAG9-targeted therapies and diagnostic tools, emphasizing the protein's potential as a biomarker for cancer diagnosis and prognosis. The ongoing research into EBAG9 seeks to elucidate its precise biological roles and to determine its viability as a therapeutic target in the treatment of hormone-responsive and other types of cancers.
